EAM
NBIX icon

EFG Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

EFG Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.31M Sell
9,305
-1,870
-17% -$253K 0.17% 156
2025
Q2 		$1.4M Buy
11,175
+1,026
+10% +$118K 0.2% 154
2025
Q1 		$1.12M Sell
10,149
-3,172
-24% -$402K 0.19% 166
2024
Q4 		$1.82M Sell
13,321
-14,190
-52% -$1.76M 0.25% 164
2024
Q3 		$3.17M Sell
27,511
-5,589
-17% -$766K 0.53% 61
2024
Q2 		$4.56M Sell
33,100
-2,764
-8% -$379K 0.79% 25
2024
Q1 		$4.94M Sell
35,864
-637
-2% -$87K 0.85% 24
2023
Q4 		$4.81M Sell
36,501
-1,627
-4% -$187K 0.91% 21
2023
Q3 		$4.29M Buy
38,128
+390
+1% +$41.1K 1.02% 27
2023
Q2 		$3.56M Buy
37,738
+3,743
+11% +$366K 0.76% 49
2023
Q1 		$3.44M Buy
33,995
+4,465
+15% +$465K 0.76% 46
2022
Q4 		$3.55M Sell
29,530
-1,139
-4% -$133K 0.8% 40
2022
Q3 		$3.26M Sell
30,669
-2,692
-8% -$273K 0.75% 46
2022
Q2 		$3.25M Buy
33,361
+2,278
+7% +$210K 0.68% 48
2022
Q1 		$2.92M Buy
+31,083
New +$2.63M 0.44% 66

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EFG Asset Management's NBIX Position: Q3 2025 in Review

EFG Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 17% in Q3 2025, selling an estimated $253K and leaving 9,305 shares worth $1.31M. The position accounts for 0.17% of the portfolio, ranked #156.

EFG Asset Management first reported a position in NBIX in Q1 2022 and has held it in 15 quarters since. The position peaked at $4.94M in Q1 2024. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • EFG Asset Management held 9,305 shares of Neurocrine Biosciences worth $1.31M as of Q3 2025.
  • EFG Asset Management sold 1,870 Neurocrine Biosciences shares in Q3 2025, an estimated $253K.
  • Neurocrine Biosciences made up 0.17% of EFG Asset Management's portfolio in Q3 2025, its #156 holding.
  • EFG Asset Management first reported a position in Neurocrine Biosciences in Q1 2022 and has held it in 15 quarters since.
  • EFG Asset Management's Neurocrine Biosciences position peaked at $4.94M in Q1 2024.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on EFG Asset Management's 13F filing for Q3 2025, filed 3 Nov 2025.